Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

ESBL Detection: Comparison of a Commercially Available Chromogenic Test for Third Generation Cephalosporine Resistance and Automated Susceptibility Testing in Enterobactericeae.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
      Cephalosporins/*pharmacology ; Drug Resistance, Bacterial/*drug effects ; Enterobacteriaceae/*metabolism ; Molecular Biology/*methods ; beta-Lactamases/*metabolism; Animals ; Anti-Bacterial Agents/pharmacology ; Cefotaxime/pharmacology ; Ceftizoxime/analogs & derivatives ; Ceftizoxime/pharmacology ; Enterobacteriaceae/drug effects ; Enterobacteriaceae/isolation & purification ; Escherichia coli/drug effects ; Escherichia coli/metabolism ; Humans ; Klebsiella/drug effects ; Klebsiella/metabolism ; Microbial Sensitivity Tests/methods ; Species Specificity ; Swine ; Cefpodoxime
    • نبذة مختصرة :
      Rapid detection and reporting of third generation cephalosporine resistance (3GC-R) and of extended spectrum betalactamases in Enterobacteriaceae (ESBL-E) is a diagnostic and therapeutic priority to avoid inefficacy of the initial antibiotic regimen. In this study we evaluated a commercially available chromogenic screen for 3GC-R as a predictive and/or confirmatory test for ESBL and AmpC activity in clinical and veterinary Enterobacteriaceae isolates. The test was highly reliable in the prediction of cefotaxime and cefpodoxime resistance, but there was no correlation with ceftazidime and piperacillin/tazobactam minimal inhibitory concentrations. All human and porcine ESBL-E tested were detected with exception of one genetically positive but phenotypically negative isolate. By contrast, AmpC detection rates lay below 30%. Notably, exclusion of piperacillin/tazobactam resistant, 3GC susceptible K1+ Klebsiella isolates increased the sensitivity and specificity of the test for ESBL detection. Our data further imply that in regions with low prevalence of AmpC and K1 positive E. coli strains chromogenic testing for 3GC-R can substitute for more time consuming ESBL confirmative testing in E. coli isolates tested positive by Phoenix or VITEK2 ESBL screen. We, therefore, suggest a diagnostic algorithm that distinguishes 3GC-R screening from primary culture and species-dependent confirmatory ESBL testing by βLACTATM and discuss the implications of MIC distribution results on the choice of antibiotic regimen.
    • Comments:
      Erratum in: PLoS One. 2018 Jun 7;13(6):e0198959. (PMID: 29879223)
    • References:
      Clin Microbiol Infect. 2008 Jan;14 Suppl 1:169-74. (PMID: 18154542)
      Biomed Res Int. 2015;2015:831074. (PMID: 25793209)
      Lancet Infect Dis. 2015 Apr;15(4):475-85. (PMID: 25716293)
      J Clin Microbiol. 2010 Apr;48(4):1019-25. (PMID: 20181902)
      Clin Infect Dis. 2013 Feb;56(4):488-95. (PMID: 23090931)
      J Antimicrob Chemother. 2004 May;53(5):888-9. (PMID: 15056644)
      Clin Microbiol Infect. 2012 Sep;18(9):894-900. (PMID: 21985560)
      Clin Microbiol Rev. 2005 Oct;18(4):657-86. (PMID: 16223952)
      Clin Infect Dis. 2006 Dec 1;43(11):1407-14. (PMID: 17083012)
      Clin Microbiol Infect. 2008 Jan;14 Suppl 1:181-4. (PMID: 18154544)
      Expert Rev Anti Infect Ther. 2008 Oct;6(5):671-83. (PMID: 18847405)
      Antimicrob Agents Chemother. 2006 Jun;50(6):2244-7. (PMID: 16723596)
      Antimicrob Agents Chemother. 2007 Jun;51(6):1987-94. (PMID: 17387156)
      J Pediatr Pharmacol Ther. 2014 Jul;19(3):156-64. (PMID: 25309145)
      J Clin Microbiol. 2013 Jun;51(6):1951-4. (PMID: 23576537)
      Clin Infect Dis. 2006 Jan 1;42(1):37-45. (PMID: 16323089)
      J Antimicrob Chemother. 2014 Apr;69(4):871-80. (PMID: 24265230)
      Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1931-9. (PMID: 22210267)
      Semin Respir Crit Care Med. 2015 Feb;36(1):56-73. (PMID: 25643271)
      J Clin Microbiol. 2014 Oct;52(10):3792-4. (PMID: 25078913)
      Euro Surveill. 2013 Aug 01;18(31):null. (PMID: 23929228)
      J Infect Chemother. 2007 Dec;13(6):390-5. (PMID: 18095087)
      Clin Microbiol Infect. 2015 Dec;21(12):1105.e1-8. (PMID: 26271718)
      Int J Med Microbiol. 2010 Aug;300(6):371-9. (PMID: 20537585)
      J Antimicrob Chemother. 2007 Dec;60(6):1375-9. (PMID: 17913719)
      Clin Microbiol Infect. 2013 Feb;19(2):141-60. (PMID: 22117544)
      J Clin Microbiol. 2014 May;52(5):1741-4. (PMID: 24574293)
      Antimicrob Agents Chemother. 2013 Jul;57(7):3092-9. (PMID: 23612198)
      Clin Infect Dis. 2015 May 1;60(9):1319-25. (PMID: 25586681)
      PLoS One. 2015 Sep 30;10(9):e0138173. (PMID: 26422606)
      Antimicrob Agents Chemother. 2009 Jun;53(6):2360-6. (PMID: 19349512)
      Antimicrob Agents Chemother. 2015 Apr;59(4):1931-4. (PMID: 25583732)
      Clin Infect Dis. 2001 Apr 15;32(8):1162-71. (PMID: 11283805)
      J Antimicrob Chemother. 2012 Jul;67(7):1569-77. (PMID: 22461311)
      Antimicrob Agents Chemother. 2015 Sep;59(9):5095-6. (PMID: 26100709)
    • الرقم المعرف:
      0 (Anti-Bacterial Agents)
      0 (Cephalosporins)
      C43C467DPE (Ceftizoxime)
      EC 3.5.2.6 (beta-Lactamases)
      N2GI8B1GK7 (Cefotaxime)
    • الموضوع:
      Date Created: 20160806 Date Completed: 20170731 Latest Revision: 20231213
    • الموضوع:
      20240628
    • الرقم المعرف:
      PMC4975492
    • الرقم المعرف:
      10.1371/journal.pone.0160203
    • الرقم المعرف:
      27494134